complication after solid organ transplantation. It is believed that more than 50% of transplant recipients are affected by this troublesome complication, which causes graft failure and mortality if the infection is not treated promptly. 1 The risk factors include CMV-seronegative recipients who receive organs from CMV-seropositive donors or CMV-seropositive recipients who received anti-Tcell antibodies, such as anti-thymocyte globulin or muromonab-CD3 (Orthoclone OKT3), for induction of immunosuppression. [2] [3] [4] Preemptive treatment of CMV infection is a crucial strategy in transplant recipients. Valganciclovir (VGC) has shown its superiority over the intravenous and oral form, ganciclovir, by its convenience, better bioavailability and potency. 5 It is also an effective prophylaxis for CMV infection in high-risk transplant recipients, 6 and for treatment of CMV retinitis in patients with acquired immunodeficiency syndrome. 7 Several clinical studies have reported that VGC therapy can cause varying degrees of leucopenia, which may counteract the benefits of the therapy. However, the risk factors associated with VGC-induced leucopenia in patients undergoing solid organ transplantation are still not well understood, especially in Oriental recipients. We analyzed the clinical data from before and after VGC therapy in cardiac transplant recipients to clarify the incidence of unexpected leucopenia and the risk factors.
cardial biopsy, echocardiography and coronary angiography were also arranged.
Statistical Analysis
Categorical variables were compared using Fisher's exact test. Mann-Whitney U test was used for comparison of 2 independent groups, and the pre-and post-VGC data were compared using Wilcoxon signed rank test, because normal distribution within a number of groups could not be assumed. A p-value <0.05 was considered significant. All statistical analysis was performed with SPSS (version 12.0; Chicago, IL, USA).
Results
As standard practise for cardiac transplant recipients we prescribe a cyclosporine-or tacrolimus-based triple immunosuppressive therapy regimen, which may also include mycophenolate mofetil (or mycophenolic acid), and prednisolone as the primary and long-term immunosuppressive agents. In those cardiac recipient receiving cyclosporine as an immunosuppressant, we measure 2-h post-dose concentrations (C2) for monitoring immunosuppressive status, which is generally reported to be useful and of clinical benefit for monitoring cardiac transplant patients. 8, 9 Generally speaking, the C2 is maintained at 200-300 g/L during the first 3 months after transplantation, adjusted according to renal function, and then gradually tapered to 150-250 g/L. Patients on the tacrolimus-based regimen have the tacrolimus level kept at approximately 8-15 g/L. The dosages of mycophenolate mofetil and mycophenolic acid are adjusted according to WBC count, lymphocyte subpopulation, renal function, and possible side-effects. Approximately 70% of patients are weaned off prednisolone within 1 year after transplantation.
All 61 study subjects underwent scheduled endomyocardial biopsy, echocardiography and coronary angiography to monitor rejection status. Monthly check-ups were also performed in the outpatient department.
Unexpectedly, after only 1 month of VGC administration, more than half of the present cardiac transplant recipients (32/61) had developed leucopenia. The characteristics of the patients are summarized in Table 1 . Age, height, transplantation duration, dosage of VGC, renal function and types of immunosuppressant drugs were similar between the 2 groups. However, body weight (p=0.019), body surface area (p=0.046) and body mass index (BMI) (p=0.008) differed significantly.
In the leucopenia group the WBC counts dramatically dropped in the first month (n=31) (pre-VGC 5,544 cells/mm 3 vs post-VGC 2,460 cells/mm 3 , p<0.0001) ( Table 2) , except in 1 patient in whom the reduction in WBC count occurred in the second month. To prevent leucopenia-related complications, 18 ceased taking VGC and the remaing 14 patients continued on half the previous dosage because of previous history of frequent CMV infection or disease. During follow-up of 4 months, the WBC counts rebounded within 1 month of ceasing or reducing the dosage of VGC (2,460 cells/mm 3 4 ,126 cells/mm 3 , p=0.003) (Fig 1) . It deserves mentioning here that there were 2 patients with neutropenic fever whose WBC counts fell to less than 1,000 cells/mm 3 , with absolute neutrophil counts less than 500 cells/mm 3 . In order to recover their immunity, we gave them granulocyte colony stimulating factor immediately and their WBC counts rose promptly. Because of the bone marrow suppressive effect of VGC, the need for immunosuppressive agents decreased and we found that we could reduce the daily dosage of tacrolimus from 4.24 mg to 3.16 mg (p=0.007), without a significant change in the serum concentration of tacrolimus (9.20 g/L 8.13 g/L, p=0.151) ( Table 2 ). The daily dosage of mycophenolate mofetil was also reduced from 1,655.45 mg to 1,435.68 mg (p=0.021).
In the non-leucopenia group, all completed the course of VGC treatment. Their WBC counts also dropped significantly (5,932 cells/mm 3 4 ,853 cells/mm 3 , p<0.0001) ( Table 2) in the first month, but rebounded without reduction of the VGC dosage. The decrease in the daily tacrolimus dosage in this group nearly reached significance (4.32 mg 3.96 mg, p=0.051) while the serum concentration of tacrolimus differed insignificantly (9.41 g/L 8.78 g/L, p=0.275). Otherwise, there was no significant difference in hemoglobulin, platelet counts, serum creatinine or the daily dosage of mycophenolate mofetil before and after VGC administration (Table 2 ).
In the comparison of pre-and post-VGC administration in all study recipients, the decline in the WBC counts in the first month (5,738 cells/mm 3 3,656 cells/mm 3 , p<0.0001), daily tacrolimus dosage (4.28 mg 3.52 mg, p=0.001), and the serum concentration of tacrolimus (9.30 g/L 8.43 g/L, p=0.033) had significant difference. Otherwise, there was no significant difference in hemoglobulin, platelet counts, serum creatinine or the dosage of mycophenolate mofetil before and after VGC administration ( Table 2) . The most momentous difference between the leucopenia and non-leucopenia groups was the WBC counts in the first month after VGC treatment (2,460 cells/mm 3 vs 4,853 cells/mm 3 , p<0.0001). In addition, the chance of CMV reactivation in the leucopenia group was higher than in the non-leucopenia group, though the difference did not reach significance (p=0.45) ( Table 2 ). The potentially higher CMV reactivation rate in the leucopenia group may result from incomplete treatment of VGC and the significant decrement in the recipient's immunity.
Analysis of the patients' clinical examinations revealed that the dosage of VGC in non-leucopenia group was lower than in the leucopenia group, but did not reach significant difference (654.27 mg vs 551.38 mg, p=0.130). The most significant differences between leucopenia and non-leucopenia groups (Table 1) were in body weight (63.67 kg vs 71.27 kg, p=0.019) and BMI (23.04 vs 25.83, p=0.008), suggesting that these may be the important factors for leucopenia occurrence. We reviewed the relationship between BMI and the percentage reduction in WBC counts, and found that the lower the BMI, the greater the reduction in the WBC counts (Fig 2) . The apparent cutoff value of BMI for predicting leucopenia development after VGC therapy is 24 (odds ratio =7.58, 95% confidence interval: 1.499-38.462), which has implications for Chinese cardiac recipi- ents with a BMI <24 who will presumably have a higher risk for leucopenia after VGC therapy.
Discussion
Before the introduction of VGC, we used intravenous ganciclovir to treat CMV infection, but the disease still frequently occurred in some patients. After the new drug became available in 2005, we routinely prescribed it instead for 3 months for CMV infection and the drug dosage was adjusted according to the recipient's renal function (Ccr as an indicator). Because of its potent bone marrow suppression (VGC product datasheet; Roche), the type and dosages of immunosuppressant drugs were adjusted according to the patient's clinical condition.
VGC has much better oral bioavailability than ganciclovir and is more convenient to administer, as it does not require hospitalization and intravenous access. Paya et al suggested that VGC has better efficacy in preventing CMV disease, 6 and the Canadian Society of Transplantation Consensus Workshop on CMV Management in Solid Organ Transplantation also confirmed the role of VGC in CMV prophylaxis. 10 However, there is still no consensus on the treatment of CMV disease using VGC. A paper of Fellay et al was the first to describe successful treatment with VGC of CMV disease in heart and lung transplant patients. 11 It is well known that bone marrow suppression is a possible complication of VGC; 14% of the patients according to the drug's manufacturer. Ainger et al 12 reported that preemptive therapy with VGC for CMV infection detected by PCR in either the plasma or broncho-alveolar lavage after lung transplantation seemed to be efficacious and safe, but required caution for possible hematological complications, such as leucopenia; in their study 36.8% of patients developed this complication. Taber et al 13 also reported that the overall incidence of leucopenia was 11% after VGC therapy in transplant recipients. However, in the present study the WBC counts reduced significantly in the first month after VGC therapy in nearly all the cardiac transplant recipients, and half of them developed severe leucopenia. It is apparent that the current recommended dosage of VGC is not suitable for Chinese cardiac recipients, who are generally thinner than Caucasians. We found that the BMI in the non-leucopenia group (BMI =25.83) was closer to that of Caucasians, but the patients in the leucopenia group had much lower BMI and body weight, which could be risk factors for leucopenia. On the other hand, the leucopenia complication has been previously reported in Caucasians, but not in Asians, so our report is the first to describe severe leucopenia after VGC therapy in Asian cardiac transplant recipients. Racial or genetic difference may play a role in the development of leucopenia. Once severe leucopenia develops after VGC administration, the therapy has to be ceased, which may result in CMV reactivation because of the incomplete treatment and more compromised immunity. In those circumstances, cardiac transplant recipients do not get any benefit from VGC treatment, but suffer from leucopenia and possible CMV reactivation. The appropriate dosage of VGC in Asians, and other thin cardiac transplant recipients, has to be re-evaluated to avoid leucopenia and to ensure complete treatment for CMV infection.
The immunosuppressant drugs used in the present study were mainly tacrolimus and mycophenolate mofetil (n=22 in leucopenia group and n=20 in non-leucopenia group). Eight patients in each group took cyclosporine and mycophenolate mofetil as the immunosuppressant therapy ( Table 1 ). The need for immunosuppressant drugs decreases with concomitant VGC because of its immunosuppressive potency. The daily dosage of tacrolimus in all relevant study subjects dropped 17.77% during VGC therapy (Table 2) . It is well known that renal impairment is the most common adverse effect of tacrolimus and, although the serum creatinine level before and after VGC therapy did not differ significantly, the subjects' immunosuppressive status could be maintained with a lower daily dosage of tacrolimus.
Furthermore, our analysis disclosed that BMI =24 may be a useful cutoff value for the development of leucopenia. Patients with BMI <24 had a higher risk of developing leucopenia (odds ratio =7.58, 95% confidence interval: 1.499-38.462). We recommend that the dosage of VGC for those with a BMI <24 and for Asian cardiac transplant recipients should be adjusted to 450 mg/day if the Ccr is greater than 60 ml/min, 450 mg every other day if Ccr is between 40 and 60 ml/min, 450 mg twice per week if Ccr is between 25 and 40 ml/min, or 450 mg/week if Ccr is between 10 and 25 ml/min. Furthermore, in the present study the daily dosage of tacrolimus in cardiac transplant recipients with a BMI <24 dropped from 3.53 mg to 2.54 mg (p=0.008), and those with BMI >24 dropped from 5.30 mg to 4.50 mg (p=0.066). Reduction of the daily tacrolimus dosage should be done when VGC is prescribed. It is our experience that the daily dosage of tacrolimus should be reduced 1 mg in cardiac transplant recipients with BMI <24, but a large series trial and follow-up are necessary.
Paya et al 6 reported that there was no clear association between systemic exposure to ganciclovir and the incidence of leucopenia, whereas Wiltshire et al 14 found a weak positive relation between increased ganciclovir exposure and the development of hematological adverse events. There might be some difference in systemic ganciclovir exposure between cardiac transplant recipients with lower BMI and those with a larger BMI. Further prospective research is needed to explore and clarify the possible mechanism of leucopenia development after VGC therapy in Chinese cardiac transplant recipients with different BMI.
In conclusion, severe leucopenia may occur in the first month after VGC therapy in Asian cardiac transplant recipients, especially those with a BMI <24. In such patients it is mandatory to adjust the dosage of both VGC and tacrolimus to prevent leucopenia developing. Understanding this risk factor is crucial for targeting the patient population for VGC therapy among cardiac transplant recipients.
